Company intelligence / Profile preview
Sinopharm Wuhan Biopharmaceuticals Co., Ltd.
Wuhan, Hubei Province, China
- Ownership
- Private
- Development stage
- Other
01
Overview
The company conducted a Phase 2 clinical trial for Human COVID-19 immunoglobulin (pH4) for intravenous injection (COVID-HIG) in the treatment of patients with COVID-19, which started on December 30, 2021. They also have Human prothrombin complex for Hemophilia B in IND approval stage.
- Therapeutic areas
- HematologyInfectious Diseases
- Modalities
- Blood productsPlasma-derived biotherapiesImmunoglobulins
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Sinopharm Wuhan Biopharmaceuticals Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sinopharm Wuhan Biopharmaceuticals Co., Ltd..